Chiasma (NASDAQ:CHMA) had its target price upped by investment analysts at HC Wainwright from $10.00 to $11.00 in a research report issued on Monday, The Fly reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 104.46% from the stock’s current price.
Several other equities analysts have also recently issued reports on the stock. BidaskClub upgraded shares of Chiasma from a “hold” rating to a “buy” rating in a research report on Tuesday, June 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of Chiasma in a report on Tuesday, March 17th. Zacks Investment Research downgraded Chiasma from a “hold” rating to a “sell” rating in a report on Thursday, March 19th. Finally, ValuEngine raised Chiasma from a “hold” rating to a “buy” rating in a research note on Thursday, March 5th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $11.70.
Shares of CHMA stock opened at $5.38 on Monday. Chiasma has a twelve month low of $2.88 and a twelve month high of $9.25. The stock’s fifty day simple moving average is $6.27 and its 200 day simple moving average is $5.00. The firm has a market capitalization of $222.71 million, a P/E ratio of -4.89 and a beta of 1.52.
Chiasma (NASDAQ:CHMA) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.05). On average, sell-side analysts anticipate that Chiasma will post -1.43 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the company. Meeder Asset Management Inc. boosted its position in shares of Chiasma by 799.9% during the 1st quarter. Meeder Asset Management Inc. now owns 7,190 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 6,391 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in shares of Chiasma by 166.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 10,568 shares of the biotechnology company’s stock worth $39,000 after buying an additional 6,597 shares in the last quarter. Citigroup Inc. grew its position in shares of Chiasma by 24.9% during the 1st quarter. Citigroup Inc. now owns 12,636 shares of the biotechnology company’s stock worth $46,000 after buying an additional 2,523 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Chiasma during the 1st quarter worth approximately $48,000. Finally, Alambic Investment Management L.P. acquired a new position in shares of Chiasma during the 4th quarter valued at $50,000. 75.24% of the stock is currently owned by institutional investors.
Chiasma Company Profile
Chiasma, Inc, a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Read More: Trading Ex-Dividend Strategy
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.